| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc4c25a2049ef2f2e0d8e6b7003159a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b055e43dc351a5016831bc96feb91177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcddc6486ac49b7ee640013af7522543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e40ff860c1fe3dcd156de121ca6d5964
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ab074aa979cff2598b5dec3732f4e14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa2d1d961c591358634835e5743acd06 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2003-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbef16703ed8bc8cd52378914c0812c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29ecc3b5ebc48950e0346de92b6da381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5273131e0b65dd2ee0070c2b20422c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f4bbc0df397134bbcc4592f73ef63eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9616459180ecc5325b21825b5b742c9 |
| publicationDate |
2005-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03091698-A3 |
| titleOfInvention |
Cetp genetic markers for statin-specific changes in hdl cholesterol |
| abstract |
Genetic markers in the CETP gene associated with statin-specific changes in HDL cholesterol after statin treatment are disclosed. Compositions and methods for detecting and using these CETP genetic markers in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising a statin composition approved for treating patients having one of these CETP haplotypes, methods and kits for predicting the response of an individual to a given statin treatment based on their haplotype profile, and methods for treating individuals with hyperlipidemia based on their haplotype profile. |
| priorityDate |
2002-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |